CLINICAL TRIAL SUMMARY

MDACC Study No:2013-0207 (clinicaltrials.gov NCT No: NCT01891344)
Title:A Phase 2, Open-Label Study of Rucaparib in Patients with Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Principal Investigator:Robert Coleman
Treatment Agent:Rucaparib
Study Status:Open
Study Description:The goal of this clinical research study is to learn if the experimental drug
CO-338 (rucaparib) can help to control epithelial ovarian, fallopian tube,
and/or primary peritoneal cancer. Researchers also want to learn if biomarkers
(substances in the body including DNA and RNA [the genetic materials in cells])
may be related to your reaction to the study drug. One of the goals of the
biomarker research is to identify which biomarkers are present most often in
patients that appear to benefit from treatment with rucaparib and to eventually
develop a diagnostic test to help identify patients with these biomarkers
before treatment is started. The safety of the drug will also be studied.

Hide details for General InformationGeneral Information

Disease Group:Gynecology
Phase of Study:Phase II
Treatment Agents:Rucaparib
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Clovis Oncology
Return Visit:
Home Care:


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Robert Coleman
Dept:Gynecologic Oncology
For Clinical Trial Enrollment:713-745-3357
For General Questions about Clinical Trials:1-877-MDA-6789


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults